(NASDAQ: CMRX) Chimerix's forecast annual revenue growth rate of 470.51% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 37.04%, and it is also forecast to beat the US market's average forecast revenue growth rate of 9.92%.
Chimerix's revenue in 2024 is $324,000.On average, 2 Wall Street analysts forecast CMRX's revenue for 2024 to be $2,454,622,945, with the lowest CMRX revenue forecast at $2,232,935,211, and the highest CMRX revenue forecast at $2,676,310,680. On average, 2 Wall Street analysts forecast CMRX's revenue for 2025 to be $624,472,492, with the lowest CMRX revenue forecast at $446,051,780, and the highest CMRX revenue forecast at $802,893,204.
In 2026, CMRX is forecast to generate $6,243,654,396 in revenue, with the lowest revenue forecast at $1,240,470,000 and the highest revenue forecast at $12,618,804,856.